Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy

T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregori, Silvia, Passerini, Laura, Roncarolo, Maria-Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658444/
https://www.ncbi.nlm.nih.gov/pubmed/26635807
http://dx.doi.org/10.3389/fimmu.2015.00593
_version_ 1782402516362723328
author Gregori, Silvia
Passerini, Laura
Roncarolo, Maria-Grazia
author_facet Gregori, Silvia
Passerini, Laura
Roncarolo, Maria-Grazia
author_sort Gregori, Silvia
collection PubMed
description T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
format Online
Article
Text
id pubmed-4658444
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46584442015-12-03 Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy Gregori, Silvia Passerini, Laura Roncarolo, Maria-Grazia Front Immunol Immunology T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies. Frontiers Media S.A. 2015-11-25 /pmc/articles/PMC4658444/ /pubmed/26635807 http://dx.doi.org/10.3389/fimmu.2015.00593 Text en Copyright © 2015 Gregori, Passerini and Roncarolo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gregori, Silvia
Passerini, Laura
Roncarolo, Maria-Grazia
Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title_full Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title_fullStr Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title_full_unstemmed Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title_short Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
title_sort clinical outlook for type-1 and foxp3(+) t regulatory cell-based therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658444/
https://www.ncbi.nlm.nih.gov/pubmed/26635807
http://dx.doi.org/10.3389/fimmu.2015.00593
work_keys_str_mv AT gregorisilvia clinicaloutlookfortype1andfoxp3tregulatorycellbasedtherapy
AT passerinilaura clinicaloutlookfortype1andfoxp3tregulatorycellbasedtherapy
AT roncarolomariagrazia clinicaloutlookfortype1andfoxp3tregulatorycellbasedtherapy

Ejemplares similares